Allergan and tribe to appeal PTAB’s immunity decision
Native American tribe not entitled to sovereign immunity: PTAB
Native American tribe aims to dismiss Allergan patent IPRs
tumsasedgars / iStockphoto.com
Late last week, the Patent Trial and Appeal Board (PTAB) rejected a Native American tribe’s attempt to dismiss inter partes reviews (IPRs) based on the tribe’s sovereign immunity claims.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at email@example.com.
If you have any technical issues please email tech support.
generics, Restasis, patent invalidation, Allergan, Saint Regis Mohawk Tribe, PTAB, IPR, sovereign immunity